Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum.
Identifieur interne : 000972 ( Main/Exploration ); précédent : 000971; suivant : 000973Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum.
Auteurs : C. Louapre [France] ; E. Maillart [France] ; T. Roux [France] ; V. Pourcher [France] ; G. Bussone [France] ; C. Lubetzki [France] ; C. Papeix [France]Source :
- Revue neurologique [ 0035-3787 ] ; 2020.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen (MeSH), Anticorps monoclonaux humanisés (usage thérapeutique), Betacoronavirus (MeSH), Chlorhydrate de fingolimod (usage thérapeutique), Femelle (MeSH), Humains (MeSH), Immunosuppresseurs (usage thérapeutique), Infections à coronavirus (diagnostic), Natalizumab (usage thérapeutique), Pandémies (MeSH), Pneumopathie virale (diagnostic), Sclérose en plaques chronique progressive (imagerie diagnostique), Sclérose en plaques chronique progressive (traitement médicamenteux), Sclérose en plaques récurrente-rémittente (traitement médicamenteux).
- MESH :
- diagnostic : Infections à coronavirus, Pneumopathie virale.
- imagerie diagnostique : Sclérose en plaques chronique progressive.
- traitement médicamenteux : Sclérose en plaques chronique progressive, Sclérose en plaques récurrente-rémittente.
- usage thérapeutique : Anticorps monoclonaux humanisés, Chlorhydrate de fingolimod, Immunosuppresseurs, Natalizumab.
- Adulte d'âge moyen, Betacoronavirus, Femelle, Humains, Pandémies.
English descriptors
- KwdEn :
- Antibodies, Monoclonal, Humanized (therapeutic use), Betacoronavirus (MeSH), Coronavirus Infections (diagnosis), Female (MeSH), Fingolimod Hydrochloride (therapeutic use), Humans (MeSH), Immunosuppressive Agents (therapeutic use), Middle Aged (MeSH), Multiple Sclerosis, Chronic Progressive (diagnostic imaging), Multiple Sclerosis, Chronic Progressive (drug therapy), Multiple Sclerosis, Relapsing-Remitting (drug therapy), Natalizumab (therapeutic use), Pandemics (MeSH), Pneumonia, Viral (diagnosis).
- MESH :
- chemical , therapeutic use : Antibodies, Monoclonal, Humanized, Fingolimod Hydrochloride, Immunosuppressive Agents, Natalizumab.
- diagnosis : Coronavirus Infections, Pneumonia, Viral.
- diagnostic imaging : Multiple Sclerosis, Chronic Progressive.
- drug therapy : Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Relapsing-Remitting.
- Betacoronavirus, Female, Humans, Middle Aged, Pandemics.
DOI: 10.1016/j.neurol.2020.04.009
PubMed: 32362357
PubMed Central: PMC7184008
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum.</title><author><name sortKey="Louapre, C" sort="Louapre, C" uniqKey="Louapre C" first="C" last="Louapre">C. Louapre</name><affiliation wicri:level="3"><nlm:affiliation>Institut du cerveau, ICM, Sorbonne université, hôpital de la Pitié-Salpêtrière, INSERM UMR S 1127, CNRS UMR 7225, Paris, France; Département de neurologie, hôpital Pitié-Salpetrière, AP-HP, Paris, France. Electronic address: celine.louapre@aphp.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut du cerveau, ICM, Sorbonne université, hôpital de la Pitié-Salpêtrière, INSERM UMR S 1127, CNRS UMR 7225, Paris, France; Département de neurologie, hôpital Pitié-Salpetrière, AP-HP, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Maillart, E" sort="Maillart, E" uniqKey="Maillart E" first="E" last="Maillart">E. Maillart</name><affiliation wicri:level="3"><nlm:affiliation>Institut du cerveau, ICM, Sorbonne université, hôpital de la Pitié-Salpêtrière, INSERM UMR S 1127, CNRS UMR 7225, Paris, France; Département de neurologie, hôpital Pitié-Salpetrière, AP-HP, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut du cerveau, ICM, Sorbonne université, hôpital de la Pitié-Salpêtrière, INSERM UMR S 1127, CNRS UMR 7225, Paris, France; Département de neurologie, hôpital Pitié-Salpetrière, AP-HP, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Roux, T" sort="Roux, T" uniqKey="Roux T" first="T" last="Roux">T. Roux</name><affiliation wicri:level="3"><nlm:affiliation>Institut du cerveau, ICM, Sorbonne université, hôpital de la Pitié-Salpêtrière, INSERM UMR S 1127, CNRS UMR 7225, Paris, France; Département de neurologie, hôpital Pitié-Salpetrière, AP-HP, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut du cerveau, ICM, Sorbonne université, hôpital de la Pitié-Salpêtrière, INSERM UMR S 1127, CNRS UMR 7225, Paris, France; Département de neurologie, hôpital Pitié-Salpetrière, AP-HP, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Pourcher, V" sort="Pourcher, V" uniqKey="Pourcher V" first="V" last="Pourcher">V. Pourcher</name><affiliation wicri:level="3"><nlm:affiliation>Service de maladies infectieuses et tropicales, hôpitaux universitaires Pitié-Salpêtrière Charles-Foix, Assistance publique-Hôpitaux de Paris, 75013, Paris, France; INSERM 1136, institut Pierre-Louis d'épidémiologie et de santé publique, Sorbonne université, 75013, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de maladies infectieuses et tropicales, hôpitaux universitaires Pitié-Salpêtrière Charles-Foix, Assistance publique-Hôpitaux de Paris, 75013, Paris, France; INSERM 1136, institut Pierre-Louis d'épidémiologie et de santé publique, Sorbonne université, 75013, Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Bussone, G" sort="Bussone, G" uniqKey="Bussone G" first="G" last="Bussone">G. Bussone</name><affiliation wicri:level="3"><nlm:affiliation>Département de médecine interne, hôpital Antoine-Béclère, AP-HP, Clamart, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Département de médecine interne, hôpital Antoine-Béclère, AP-HP, Clamart</wicri:regionArea><placeName><settlement type="city">Clamart</settlement></placeName></affiliation></author><author><name sortKey="Lubetzki, C" sort="Lubetzki, C" uniqKey="Lubetzki C" first="C" last="Lubetzki">C. Lubetzki</name><affiliation wicri:level="3"><nlm:affiliation>Institut du cerveau, ICM, Sorbonne université, hôpital de la Pitié-Salpêtrière, INSERM UMR S 1127, CNRS UMR 7225, Paris, France; Département de neurologie, hôpital Pitié-Salpetrière, AP-HP, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut du cerveau, ICM, Sorbonne université, hôpital de la Pitié-Salpêtrière, INSERM UMR S 1127, CNRS UMR 7225, Paris, France; Département de neurologie, hôpital Pitié-Salpetrière, AP-HP, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Papeix, C" sort="Papeix, C" uniqKey="Papeix C" first="C" last="Papeix">C. Papeix</name><affiliation wicri:level="3"><nlm:affiliation>Institut du cerveau, ICM, Sorbonne université, hôpital de la Pitié-Salpêtrière, INSERM UMR S 1127, CNRS UMR 7225, Paris, France; Département de neurologie, hôpital Pitié-Salpetrière, AP-HP, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut du cerveau, ICM, Sorbonne université, hôpital de la Pitié-Salpêtrière, INSERM UMR S 1127, CNRS UMR 7225, Paris, France; Département de neurologie, hôpital Pitié-Salpetrière, AP-HP, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32362357</idno><idno type="pmid">32362357</idno><idno type="doi">10.1016/j.neurol.2020.04.009</idno><idno type="pmc">PMC7184008</idno><idno type="wicri:Area/Main/Corpus">001466</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001466</idno><idno type="wicri:Area/Main/Curation">001466</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001466</idno><idno type="wicri:Area/Main/Exploration">001466</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum.</title><author><name sortKey="Louapre, C" sort="Louapre, C" uniqKey="Louapre C" first="C" last="Louapre">C. Louapre</name><affiliation wicri:level="3"><nlm:affiliation>Institut du cerveau, ICM, Sorbonne université, hôpital de la Pitié-Salpêtrière, INSERM UMR S 1127, CNRS UMR 7225, Paris, France; Département de neurologie, hôpital Pitié-Salpetrière, AP-HP, Paris, France. Electronic address: celine.louapre@aphp.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut du cerveau, ICM, Sorbonne université, hôpital de la Pitié-Salpêtrière, INSERM UMR S 1127, CNRS UMR 7225, Paris, France; Département de neurologie, hôpital Pitié-Salpetrière, AP-HP, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Maillart, E" sort="Maillart, E" uniqKey="Maillart E" first="E" last="Maillart">E. Maillart</name><affiliation wicri:level="3"><nlm:affiliation>Institut du cerveau, ICM, Sorbonne université, hôpital de la Pitié-Salpêtrière, INSERM UMR S 1127, CNRS UMR 7225, Paris, France; Département de neurologie, hôpital Pitié-Salpetrière, AP-HP, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut du cerveau, ICM, Sorbonne université, hôpital de la Pitié-Salpêtrière, INSERM UMR S 1127, CNRS UMR 7225, Paris, France; Département de neurologie, hôpital Pitié-Salpetrière, AP-HP, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Roux, T" sort="Roux, T" uniqKey="Roux T" first="T" last="Roux">T. Roux</name><affiliation wicri:level="3"><nlm:affiliation>Institut du cerveau, ICM, Sorbonne université, hôpital de la Pitié-Salpêtrière, INSERM UMR S 1127, CNRS UMR 7225, Paris, France; Département de neurologie, hôpital Pitié-Salpetrière, AP-HP, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut du cerveau, ICM, Sorbonne université, hôpital de la Pitié-Salpêtrière, INSERM UMR S 1127, CNRS UMR 7225, Paris, France; Département de neurologie, hôpital Pitié-Salpetrière, AP-HP, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Pourcher, V" sort="Pourcher, V" uniqKey="Pourcher V" first="V" last="Pourcher">V. Pourcher</name><affiliation wicri:level="3"><nlm:affiliation>Service de maladies infectieuses et tropicales, hôpitaux universitaires Pitié-Salpêtrière Charles-Foix, Assistance publique-Hôpitaux de Paris, 75013, Paris, France; INSERM 1136, institut Pierre-Louis d'épidémiologie et de santé publique, Sorbonne université, 75013, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de maladies infectieuses et tropicales, hôpitaux universitaires Pitié-Salpêtrière Charles-Foix, Assistance publique-Hôpitaux de Paris, 75013, Paris, France; INSERM 1136, institut Pierre-Louis d'épidémiologie et de santé publique, Sorbonne université, 75013, Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Bussone, G" sort="Bussone, G" uniqKey="Bussone G" first="G" last="Bussone">G. Bussone</name><affiliation wicri:level="3"><nlm:affiliation>Département de médecine interne, hôpital Antoine-Béclère, AP-HP, Clamart, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Département de médecine interne, hôpital Antoine-Béclère, AP-HP, Clamart</wicri:regionArea><placeName><settlement type="city">Clamart</settlement></placeName></affiliation></author><author><name sortKey="Lubetzki, C" sort="Lubetzki, C" uniqKey="Lubetzki C" first="C" last="Lubetzki">C. Lubetzki</name><affiliation wicri:level="3"><nlm:affiliation>Institut du cerveau, ICM, Sorbonne université, hôpital de la Pitié-Salpêtrière, INSERM UMR S 1127, CNRS UMR 7225, Paris, France; Département de neurologie, hôpital Pitié-Salpetrière, AP-HP, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut du cerveau, ICM, Sorbonne université, hôpital de la Pitié-Salpêtrière, INSERM UMR S 1127, CNRS UMR 7225, Paris, France; Département de neurologie, hôpital Pitié-Salpetrière, AP-HP, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Papeix, C" sort="Papeix, C" uniqKey="Papeix C" first="C" last="Papeix">C. Papeix</name><affiliation wicri:level="3"><nlm:affiliation>Institut du cerveau, ICM, Sorbonne université, hôpital de la Pitié-Salpêtrière, INSERM UMR S 1127, CNRS UMR 7225, Paris, France; Département de neurologie, hôpital Pitié-Salpetrière, AP-HP, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut du cerveau, ICM, Sorbonne université, hôpital de la Pitié-Salpêtrière, INSERM UMR S 1127, CNRS UMR 7225, Paris, France; Département de neurologie, hôpital Pitié-Salpetrière, AP-HP, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></analytic><series><title level="j">Revue neurologique</title><idno type="ISSN">0035-3787</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Betacoronavirus (MeSH)</term><term>Coronavirus Infections (diagnosis)</term><term>Female (MeSH)</term><term>Fingolimod Hydrochloride (therapeutic use)</term><term>Humans (MeSH)</term><term>Immunosuppressive Agents (therapeutic use)</term><term>Middle Aged (MeSH)</term><term>Multiple Sclerosis, Chronic Progressive (diagnostic imaging)</term><term>Multiple Sclerosis, Chronic Progressive (drug therapy)</term><term>Multiple Sclerosis, Relapsing-Remitting (drug therapy)</term><term>Natalizumab (therapeutic use)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (diagnosis)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen (MeSH)</term><term>Anticorps monoclonaux humanisés (usage thérapeutique)</term><term>Betacoronavirus (MeSH)</term><term>Chlorhydrate de fingolimod (usage thérapeutique)</term><term>Femelle (MeSH)</term><term>Humains (MeSH)</term><term>Immunosuppresseurs (usage thérapeutique)</term><term>Infections à coronavirus (diagnostic)</term><term>Natalizumab (usage thérapeutique)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (diagnostic)</term><term>Sclérose en plaques chronique progressive (imagerie diagnostique)</term><term>Sclérose en plaques chronique progressive (traitement médicamenteux)</term><term>Sclérose en plaques récurrente-rémittente (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Fingolimod Hydrochloride</term><term>Immunosuppressive Agents</term><term>Natalizumab</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Multiple Sclerosis, Chronic Progressive</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Multiple Sclerosis, Chronic Progressive</term><term>Multiple Sclerosis, Relapsing-Remitting</term></keywords><keywords scheme="MESH" qualifier="imagerie diagnostique" xml:lang="fr"><term>Sclérose en plaques chronique progressive</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Sclérose en plaques chronique progressive</term><term>Sclérose en plaques récurrente-rémittente</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Chlorhydrate de fingolimod</term><term>Immunosuppresseurs</term><term>Natalizumab</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term><term>Female</term><term>Humans</term><term>Middle Aged</term><term>Pandemics</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Betacoronavirus</term><term>Femelle</term><term>Humains</term><term>Pandémies</term></keywords></textClass></profileDesc></teiHeader></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32362357</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>11</Day></DateCompleted><DateRevised><Year>2020</Year><Month>06</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0035-3787</ISSN><JournalIssue CitedMedium="Internet"><Volume>176</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>06</Month></PubDate></JournalIssue><Title>Revue neurologique</Title><ISOAbbreviation>Rev. Neurol. (Paris)</ISOAbbreviation></Journal><ArticleTitle>Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum.</ArticleTitle><Pagination><MedlinePgn>523-525</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0035-3787(20)30546-4</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neurol.2020.04.009</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Louapre</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institut du cerveau, ICM, Sorbonne université, hôpital de la Pitié-Salpêtrière, INSERM UMR S 1127, CNRS UMR 7225, Paris, France; Département de neurologie, hôpital Pitié-Salpetrière, AP-HP, Paris, France. Electronic address: celine.louapre@aphp.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maillart</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institut du cerveau, ICM, Sorbonne université, hôpital de la Pitié-Salpêtrière, INSERM UMR S 1127, CNRS UMR 7225, Paris, France; Département de neurologie, hôpital Pitié-Salpetrière, AP-HP, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roux</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institut du cerveau, ICM, Sorbonne université, hôpital de la Pitié-Salpêtrière, INSERM UMR S 1127, CNRS UMR 7225, Paris, France; Département de neurologie, hôpital Pitié-Salpetrière, AP-HP, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pourcher</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Service de maladies infectieuses et tropicales, hôpitaux universitaires Pitié-Salpêtrière Charles-Foix, Assistance publique-Hôpitaux de Paris, 75013, Paris, France; INSERM 1136, institut Pierre-Louis d'épidémiologie et de santé publique, Sorbonne université, 75013, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bussone</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Département de médecine interne, hôpital Antoine-Béclère, AP-HP, Clamart, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lubetzki</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institut du cerveau, ICM, Sorbonne université, hôpital de la Pitié-Salpêtrière, INSERM UMR S 1127, CNRS UMR 7225, Paris, France; Département de neurologie, hôpital Pitié-Salpetrière, AP-HP, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papeix</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institut du cerveau, ICM, Sorbonne université, hôpital de la Pitié-Salpêtrière, INSERM UMR S 1127, CNRS UMR 7225, Paris, France; Département de neurologie, hôpital Pitié-Salpetrière, AP-HP, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Rev Neurol (Paris)</MedlineTA><NlmUniqueID>2984779R</NlmUniqueID><ISSNLinking>0035-3787</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000069442">Natalizumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>A10SJL62JY</RegistryNumber><NameOfSubstance UI="C533411">ocrelizumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>G926EC510T</RegistryNumber><NameOfSubstance UI="D000068876">Fingolimod Hydrochloride</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068876" MajorTopicYN="N">Fingolimod Hydrochloride</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020528" MajorTopicYN="N">Multiple Sclerosis, Chronic Progressive</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020529" MajorTopicYN="N">Multiple Sclerosis, Relapsing-Remitting</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069442" MajorTopicYN="N">Natalizumab</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>04</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>04</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32362357</ArticleId><ArticleId IdType="pii">S0035-3787(20)30546-4</ArticleId><ArticleId IdType="doi">10.1016/j.neurol.2020.04.009</ArticleId><ArticleId IdType="pmc">PMC7184008</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neurology. 2020 Jun 2;94(22):949-952</Citation><ArticleIdList><ArticleId IdType="pubmed">32241953</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Oncol. 2020 Mar 26;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32224151</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Rheum Dis. 2020 May;79(5):667-668</Citation><ArticleIdList><ArticleId IdType="pubmed">32241793</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Transplant. 2020 Mar 17;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32181990</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2017 Jan 19;376(3):209-220</Citation><ArticleIdList><ArticleId IdType="pubmed">28002688</ArticleId></ArticleIdList></Reference><Reference><Citation>Mult Scler Relat Disord. 2020 Apr;39:102073</Citation><ArticleIdList><ArticleId IdType="pubmed">32334820</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Transplant. 2020 Apr 3;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32243697</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Île-de-France</li></region><settlement><li>Clamart</li><li>Paris</li></settlement></list><tree><country name="France"><region name="Île-de-France"><name sortKey="Louapre, C" sort="Louapre, C" uniqKey="Louapre C" first="C" last="Louapre">C. Louapre</name></region><name sortKey="Bussone, G" sort="Bussone, G" uniqKey="Bussone G" first="G" last="Bussone">G. Bussone</name><name sortKey="Lubetzki, C" sort="Lubetzki, C" uniqKey="Lubetzki C" first="C" last="Lubetzki">C. Lubetzki</name><name sortKey="Maillart, E" sort="Maillart, E" uniqKey="Maillart E" first="E" last="Maillart">E. Maillart</name><name sortKey="Papeix, C" sort="Papeix, C" uniqKey="Papeix C" first="C" last="Papeix">C. Papeix</name><name sortKey="Pourcher, V" sort="Pourcher, V" uniqKey="Pourcher V" first="V" last="Pourcher">V. Pourcher</name><name sortKey="Roux, T" sort="Roux, T" uniqKey="Roux T" first="T" last="Roux">T. Roux</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000972 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000972 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32362357
|texte= Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32362357" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidFranceV1
| This area was generated with Dilib version V0.6.37. |  |